Polyestradiol phosphate

Polyestradiol phosphate (PEP), sold under the brand name Estradurin, is an estrogen medication which is used primarily in the treatment of prostate cancer in men.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 13 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Polyestradiol phosphate (PEP), sold under the brand name Estradurin, is an estrogen medication which is used primarily in the treatment of prostate cancer in men. It is also used in women to treat breast cancer, as a component of hormone therapy to treat low estrogen levels and menopausal symptoms, and as a component of feminizing hormone therapy for transgender women.

It is given by injection into muscle once every four weeks. Common side effects of PEP include headache, breast tenderness, breast development, feminization, sexual dysfunction, infertility, and vaginal bleeding. PEP is an estrogen and hence is an agonist of the estrogen receptor, the biological target of estrogens like estradiol.

It is an estrogen ester in the form of a polymer and is an extremely long-lasting prodrug of estradiol in the body. The biological half-life of PEP is more than two months. Because PEP works by being converted into estradiol, it is considered to be a natural and bioidentical form of estrogen.

The safety profile of parenteral estradiol esters like PEP is greatly improved relative to synthetic oral estrogens like ethinylestradiol and diethylstilbestrol. PEP was discovered around 1953 and was introduced for medical use in the United States in 1957.…

Polyestradiol phosphate (PEP), sold under the brand name Estradurin, is an estrogen medication which is used primarily in the treatment of prostate cancer in men. It is also used in women to treat breast cancer, as a component of hormone therapy to treat low estrogen levels and menopausal symptoms, and as a component of feminizing hormone therapy for transgender women.

It is given by injection into muscle once every four weeks. Common side effects of PEP include headache, breast tenderness, breast development, feminization, sexual dysfunction, infertility, and vaginal bleeding. PEP is an estrogen and hence is an agonist of the estrogen receptor, the biological target of estrogens like estradiol.

It is an estrogen ester in the form of a polymer and is an extremely long-lasting prodrug of estradiol in the body. The biological half-life of PEP is more than two months. Because PEP works by being converted into estradiol, it is considered to be a natural and bioidentical form of estrogen.

The safety profile of parenteral estradiol esters like PEP is greatly improved relative to synthetic oral estrogens like ethinylestradiol and diethylstilbestrol. PEP was discovered around 1953 and was introduced for medical use in the United States in 1957.

Along with estradiol undecylate and estradiol valerate, it has been frequently used in the United States and Europe as a parenteral form of estrogen to treat men with prostate cancer. However, it is no longer available in the United States and Europe.

Medical uses

PEP is used as an intramuscular injection for estrogen therapy of prostate cancer in men. It is also used to treat breast cancer in women who are at least 5 years postmenopausal. In addition, PEP is used in hormone replacement therapy for low estrogen levels due to hypogonadism or menopause in women.

It is also used in feminizing hormone therapy for transgender women. PEP is a form of high-dose estrogen therapy. After an injection, it very slowly releases the active agent estradiol over at least several months.

PEP has been compared to combined androgen blockade (CAB; castration plus flutamide) for the treatment of prostate cancer in a large randomized clinical trial of 915 patients. At 18.5 months, there was no difference in survival or cardiovascular toxicity between the two treatment modalities.

These findings suggest that parenteral forms of estradiol may have similar effectiveness and safety relative to androgen deprivation therapy (ADT) in the treatment of prostate cancer. In addition, estrogens may have significant advantages relative to ADT in terms of bone loss and fractures, hot flashes, sexual function, and quality of life, as well as considerable cost savings with parenteral forms of estradiol compared to analogue therapy.

On the other hand, breast tenderness and gynecomastia occur at very high rates with estrogens, whereas incidences are low with castration and CAB. However, gynecomastia with estrogens is generally only mild-to-moderate in severity and is usually only modestly discomforting.

In addition, gynecomastia caused by estrogens can be prevented with prophylactic irradiation of the breasts or can be remediated with mastectomy. PEP has been studied for the treatment of prostate cancer at dosages of 160 mg/month (three studies) and 240 mg/month (four studies).

At a dosage of 160 mg/month, PEP incompletely suppresses testosterone levels, failing to reach the castrate range, and is significantly inferior to orchiectomy in slowing disease progression. Conversely, PEP at a dosage of 240 mg/month results in greater testosterone suppression, into the castrate range similarly to orchiectomy, and is equivalent to orchiectomy in effectiveness.

For prostate cancer in men, PEP is usually given at a dosage of 80 to 320 mg every 4 weeks for the first 2 to 3 months to rapidly build up estradiol levels. Thereafter, to maintain estradiol levels, the dosage is adjusted down usually to 40 to 160 mg every 4 weeks based on clinical findings and laboratory parameters.

For breast cancer and low estrogen levels in women, the dosage is 40 to 80 mg every 4 weeks. For transgender women, the dosage is 80 to 160 mg every 4 weeks.

Available forms

PEP is provided in the form of powder or an aqueous solution in vials and ampoules alone or in combination with mepivacaine and/or nicotinamide (vitamin B 3 ) for administration via intramuscular injection. Mepivacaine is a local anaesthetic and is used to avoid a burning sensation during injection of PEP. Each vial/ampoule of Estradurin contains 80 mg PEP, 5 mg mepivacaine hydrochloride, 40 mg nicotinamide, and 2 mL water.

Contraindications

The contraindications of PEP are largely the same as those of estradiol and include: Hypersensitivity to PEP, mepivacaine, or other ingredients Known, previous, or suspected breast cancer or other estrogen-dependent malignant tumors (e.g., endometrial cancer) Vaginal bleeding of unknown cause or untreated endometrial hyperplasia Thrombosis and related, including active thrombophlebitis, former or current venous thromboembolism (deep vein thrombosis, pulmonary embolism), active or recent arterial thromboembolism (e.g., angina, myocardial infarction), or known thrombophilia (e.g., protein C deficiency, protein S deficiency, antithrombin deficiency) Severe arrhythmia, hypotension, hypertension, or lipid metabolism disorders Cerebrovascular events (i.e., stroke) Acute liver disease or previously confirmed liver disease, with abnormal liver function tests or jaundice (e.g., Dubin–Johnson syndrome, Rotor syndrome) Severe hepatic dysfunction Others including porphyria, sickle cell anemia, otosclerosis, or myasthenia gravis Pregnancy, lactation, and breastfeeding

Side effects

Systematic studies of the side effects of PEP are lacking. However, its side effects are assumed to be identical to those of estradiol and other estradiol esters. The side effects of PEP are partially dependent on sex.

Common or frequent (>10%) side effects are considered to include headache, abdominal pain, nausea, rash, pruritus, loss of libido, erectile dysfunction, breast tenderness, gynecomastia, feminization, demasculinization, infertility, and vaginal bleeding or spotting. Side effects that occur occasionally or uncommonly (0.1–1%) include sodium and water retention, edema, hypersensitivity, breast tension, depression, dizziness, visual disturbances, palpitations, dyspepsia, erythema nodosum, urticaria, and chest pain.

All other side effects of PEP are considered to be rare. The rare ( 50 ) of PEP in mice is approximately 700 mg/kg. PEP has been administered in total amounts of 2,000 to 3,000 mg over several months in patients with cancer without toxicity observed.

The most likely sign of overdose is reversible feminization, namely gynecomastia. Other symptoms of estrogen overdosage may include nausea, vomiting, bloating, increased weight, water retention, breast tenderness, vaginal discharge, heavy legs, and leg cramps. These side effects can be diminished by reducing the estrogen dosage.

There is no specific antidote for overdose of PEP. Treatment of PEP overdose should be based on symptoms.

Pharmacodynamics

, the active form of PEP.]] PEP is an estradiol ester in the form of a polymer and is an extremely long-lasting prodrug of estradiol. As such, it is an estrogen, or an agonist of the estrogen receptors.

PEP has antigonadotropic and functional antiandrogenic effects due to its estrogenic activity. A single repeat unit of PEP, corresponding to estradiol phosphate (minus OH 2 ), is of about 23% higher molecular weight than estradiol due to the presence of its C17β phosphate ester. Because PEP is a prodrug of estradiol, it is considered to be a natural and bioidentical form of estrogen.

PEP is a strong inhibitor of several enzymes, including acid phosphatase, alkaline phosphatase, and hyaluronidase, in vitro. In light of the fact that phosphatases, which cleave PEP into estradiol and phosphoric acid, are present in most tissues in the body, it has been said that the long elimination half-life and slow release of PEP are somewhat surprising.

It is thought that PEP may inhibit its own metabolism.

Antigonadotropic effects

PEP has antigonadotropic effects due to its estrogenic activity. It has been found to suppress testosterone levels in men by 55%, 75%, and 85% at intramuscular dosages of 80, 160, and 240 mg every 4 weeks, respectively.

A single intramuscular injection of 320 mg PEP in men has been found to suppress testosterone levels to within the castrate range ( max (time to maximal concentrations) for estradiol was about 16 days. PEP has a duration of approximately 1 month with a single dose of 40 mg, 2 months with 80 mg, and 4 months with 160 mg.

PEP reaches the bloodstream within hours after an injection (90% after 24 hours), where it circulates, and is accumulated in the reticuloendothelial system. Estradiol is then cleaved from the polymer by phosphatases, although very slowly.

Levels of estradiol in men with intramuscular injections of PEP once every 4 weeks were about 350 pg/mL with 160 mg, 450 pg/mL with 240 mg, and almost 700 pg/mL with 320 mg, all measured after 6 months of treatment. With monthly injections, steady-state estradiol concentrations are reached after 6 to 12 months.

Estradiol is metabolized primarily in the liver by CYP3A4 and other cytochrome P450 enzymes, and is metabolized to a lesser extent in extrahepatic tissues. The metabolites are mainly excreted in urine via the kidneys. Early studies found that a dosage of 80 mg PEP every 4 weeks rapidly produced relatively high mean estradiol levels of about 400 to 800 pg/mL.

These levels are similar to those of 100 mg estradiol undecylate every month, which has been found to produce estradiol levels of around 500 to 600 pg/mL. As a result, it has previously been said that 80 mg PEP per month and 100 mg estradiol undecylate per month are roughly equivalent.

However, subsequent studies showed that this dosage of PEP actually achieves much lower estradiol levels than originally demonstrated.

Chemistry

PEP is a synthetic estrane steroid and the C17β phosphoric acid (phosphate) ester of estradiol (estradiol 17β-phosphate) in the form of a polymer. It is also known as estradiol polymer with phosphoric acid or as estradiol 17β-phosphate polymer, as well as estra-1,3,5(10)-triene-3,17β-diol 17β-phosphate polymer.

It has been determined via ultracentrifugation that the mean molecular weight of PEP corresponds to a chain length of approximately 13 repeat units of estradiol 17β-phosphate. PEP is closely related to polyestriol phosphate (Gynäsan, Klimadurin, Triodurin) and polytestosterone phloretin phosphate (never commercialized), which are estriol and testosterone esters in the forms of polymers, respectively.

It is also related to polydiethylstilbestrol phosphate (never commercialized), a diethylstilbestrol ester in the form of a polymer.

Solubility

PEP is of very low solubility in water, acetone, chloroform, dioxane, and ethanol, but dissolves readily in bases, especially in aqueous pyridine.

Synthesis

Like polyphosphates of polyphenols, PEP can be prepared from the monomer (in this case estradiol) and phosphoryl chloride. The latter reacts with both the phenolic hydroxyl group in position 3 and the aliphatic one in position 17β. The molecular mass of the resulting polymer can be controlled by interrupting the reaction after a given time: the longer the reaction is allowed to continue, the higher the mass.

History

Pharmacological experiments on estradiol phosphates conducted around 1950 gave rise to the hypothesis that estradiol 3,17β-diphosphate acted as an inhibitor of kidney alkaline phosphatase. When the same scientists wanted to synthesize simple phosphates of phloretin, a compound found in apple tree leaves, they accidentally created a polymer instead.

This was later shown to exhibit the same anti-phosphatase properties as estradiol diphosphate, and so it was hypothesized that the original finding was due to contamination with estradiol phosphate polymers. Consequently, these polymers were studied in more detail, which resulted in the development of PEP as early as 1953 and its subsequent introduction for medical use in 1957 in the United States.

PEP remained on the market in the United States until at least 2000. It was last known to be marketed in European countries in 2018 but was eventually discontinued in most or all other countries.

Generic names

Polyestradiol phosphate is the generic name of the drug and its and . It is also known by its developmental code name Leo-114.

Brand names

PEP was marketed exclusively under the brand name Estradurin or Estradurine.

Availability

PEP has been marketed in the United States and widely throughout Europe, including in Austria, Belgium, the Czech Republic, Denmark, Finland, Germany, Italy, the Netherlands, Norway, Russia, Spain, Sweden, Switzerland, Ukraine, and the United Kingdom. It is no longer available in the United States and Europe.

Research

PEP has been studied as a means of hormonal breast enhancement in women. A combination of PEP and medroxyprogesterone acetate was studied in women as a long-lasting combined injectable contraceptive for use by intramuscular injection once every three months.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1368648453 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

35 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.